PubMed

Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy.

Moreno SF, Paloma JB.

Br J Ophthalmol. 2008 Jun;92(6):866-7. No abstract available. PMID: 18523097 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab: new drug. Macular degeneration: second-line use due to risks.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):3-6.PMID: 18354841 [PubMed - indexed for MEDLINE]Related articles

[VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment]

Wylegała E, Teper SJ.

Klin Oczna. 2007;109(1-3):97-100. Review. Polish. PMID: 17687925 [PubMed - indexed for MEDLINE]Related articles

Treating age-related macular degeneration - interaction of VEGF-antagonists with their target.

Klettner A, Roider J.

Mini Rev Med Chem. 2009 Aug;9(9):1127-35. Review.PMID: 19689408 [PubMed - indexed for MEDLINE]Related articles

A view on new drugs for macular degeneration.

[No authors listed]

Drug Ther Bull. 2007 Jul;45(7):49-52. Review.PMID: 17718304 [PubMed - indexed for MEDLINE]Related articles

Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.

Farah SE.

Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug;39(4):294-8.PMID: 18717434 [PubMed - indexed for MEDLINE]Related articles

[Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration]

Ambresin A, Mantel I.

Rev Med Suisse. 2007 Jan 17;3(94):137-41. Review. French. PMID: 17354539 [PubMed - indexed for MEDLINE]Related articles

[The current state and issues of medical treatment for age-related macular degeneration]

Ishida S.

Nippon Yakurigaku Zasshi. 2008 Jan;131(1):47-9. Japanese. No abstract available. PMID: 18187884 [PubMed - indexed for MEDLINE]Related articles

Therapeutic anti-VEGF antibodies.

Lien S, Lowman HB.

Handb Exp Pharmacol. 2008;(181):131-50. Review.PMID: 18071944 [PubMed - indexed for MEDLINE]Related articles

Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.

Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM; American Academy of Ophthalmology.

Ophthalmology. 2008 Oct;115(10):1837-46.PMID: 18929163 [PubMed - indexed for MEDLINE]Related articles

Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.

van Wijngaarden P, Qureshi SH.

Clin Exp Optom. 2008 Sep;91(5):427-37. Epub 2008 Jul 10. Review.PMID: 18637105 [PubMed - indexed for MEDLINE]Related articles

Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

Ziemssen F, Heiduschka P, Schraermeyer U; Tübingen Bevacizumab Study Group.

Retina. 2007 Oct;27(8):1154-6; author reply 1156-8. No abstract available. PMID: 18040264 [PubMed - indexed for MEDLINE]Related articles

[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?]

Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.

Harefuah. 2008 Jul;147(7):605-6, 662. Hebrew. PMID: 18814519 [PubMed - indexed for MEDLINE]Related articles

[Age-related macular degeneration and antivascular endothelial growth factor: a review]

Fajnkuchen F, Cohen SY.

J Fr Ophtalmol. 2008 Jan;31(1):94-110. French. PMID: 18401308 [PubMed - indexed for MEDLINE]Related articlesFree article

[New drugs; pegaptanib and ranibizumab]

van Bronswijk H, Dubois EA, van Meurs JC, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Jan 12;152(2):82-4. Review. Dutch. PMID: 18265796 [PubMed - indexed for MEDLINE]Related articles

[Angiogenesis inhibitors for vision loss. Ranibizumab for macular degeneration]

Mohr-Andrä M, Mohr K.

Pharm Unserer Zeit. 2007;36(6):437-40. Review. German. PMID: 17957687 [PubMed - indexed for MEDLINE]Related articles

[Ranibizumab (Lucentis) in the treatment of age-related macular degeneration]

Studnicka J.

Cesk Slov Oftalmol. 2009 May;65(3):107-11. Review. Czech. No abstract available. PMID: 19642358 [PubMed - indexed for MEDLINE]Related articles

Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.

Klettner A, Roider J.

Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523-7. Epub 2008 Apr 25.PMID: 18441313 [PubMed - indexed for MEDLINE]Related articlesFree article

Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration.

Rensch F, Jonas JB.

Acta Ophthalmol. 2008 Sep;86(6):696-7. No abstract available. PMID: 18752522 [PubMed - indexed for MEDLINE]Related articles

[Bevacizumab or ranibizumab, or the tale of Robin Hood and King Richard Lion Heart]

Monés J.

Arch Soc Esp Oftalmol. 2007 Sep;82(9):529-30. Spanish. No abstract available. PMID: 17846939 [PubMed - indexed for MEDLINE]Related articlesFree article